8-K: Sight Sciences Reports Mixed Q4, Full-Year 2025 Results

Sight Sciences announced preliminary unaudited financial highlights for Q4 and full year 2025, showing strong Q4 revenue growth but a full-year decline.

Summary

• Fourth quarter 2025 total revenue is expected to be in the range of $20.3 million to $20.4 million, representing an increase of 7% at the estimated midpoint compared to the prior year period.
• Surgical Glaucoma revenues for Q4 2025 are expected to be in the range of $19.6 million to $19.7 million, an increase of 5% at the estimated midpoint compared to the prior year period.
• Dry Eye revenues for Q4 2025 are expected to be approximately $0.7 million, an increase of approximately 130% compared to the prior year period.
• Full year 2025 total revenue is expected to be in the range of $77.3 million to $77.4 million, a decrease of 3% at the estimated midpoint compared to the prior year.
• Surgical Glaucoma revenues for full year 2025 are expected to be in the range of $75.6 million to $75.7 million, which is flat at the estimated midpoint compared to the prior year.
• Dry Eye revenues for full year 2025 are expected to be approximately $1.6 million, compared to $4.0 million in 2024.
• Cash and cash equivalents as of December 31, 2025, were approximately $92 million, compared to $92.4 million as of September 30, 2025.
• Cash used in the fourth quarter totaled approximately $0.4 million, reflecting continued operational discipline.
• Cash used during the full year 2025 totaled approximately $28 million.

Sentiment

Score: 6

Explanation: The company reported strong preliminary Q4 revenue growth and effective cash management, alongside significant progress in Dry Eye reimbursement. However, the full-year revenue is expected to decline, primarily due to a substantial drop in Dry Eye revenue compared to the prior year, indicating a mixed performance.

Positives

• Fourth quarter 2025 total revenue is expected to increase by 7% at the estimated midpoint compared to the prior year period.
• Fourth quarter 2025 Dry Eye revenue is expected to increase by approximately 130% compared to the prior year period.
• Strong cash management in the fourth quarter, with only approximately $0.4 million in cash used.
• Achieved significant Dry Eye reimbursement milestones, including the establishment of two Medicare Administrative Contractor fee schedules.
• Received positive early validation of the reimbursed interventional Dry Eye business model.
• Maintained continued Surgical Glaucoma momentum.
• Management expressed confidence in the growth outlook, operational discipline, and path toward cash flow breakeven without requiring additional equity capital.

Negatives

• Full year 2025 total revenue is expected to decrease by 3% at the estimated midpoint compared to the prior year.
• Full year 2025 Dry Eye revenues are expected to be approximately $1.6 million, a significant decrease compared to $4.0 million in 2024.
• Cash used during the full year 2025 totaled approximately $28 million.

Risks

• The preliminary, unaudited financial results are estimates prepared by management and are subject to revision until the completion of the company's 2025 audit.
• Actual results may differ materially from these estimates due to the completion of year-end accounting procedures and adjustments, execution of internal control over financial reporting, completion of the audit, and subsequent events prior to the formal issuance of audited financial statements.

Future Outlook

Management is confident in the company's growth outlook, operational discipline, and path toward cash flow breakeven without requiring additional equity capital. Complete fourth quarter and full year 2025 financial results are expected to be announced in March 2026.

Management Comments

• "We are pleased with our progress in the fourth quarter, including approximately 7% revenue growth compared to the prior year period, strong cash management, significant Dry Eye reimbursement milestones, and continued Surgical Glaucoma momentum."
• "Key Dry Eye achievements include the establishment of two Medicare Administrative Contractor fee schedules and positive early validation of our reimbursed interventional Dry Eye business model."
• "As we continue building a leading interventional eye care company, we remain confident in our growth outlook, operational discipline, and path toward cash flow breakeven without requiring additional equity capital."

Industry Context

Sight Sciences operates in the eyecare technology sector, focusing on innovative interventional solutions for prevalent eye diseases like glaucoma and dry eye. The company's progress in Dry Eye reimbursement and validation of its business model suggests a strategic focus on expanding market access and adoption for its technologies within the competitive ophthalmology device market.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Mixed impact due to strong Q4 performance and cash management, but full-year revenue decline and significant drop in Dry Eye revenue. Positive outlook on achieving cash flow breakeven without equity dilution.
• Patients: Continued development and commercialization of innovative interventional technologies for glaucoma and dry eye aim to improve patient lives.
• Healthcare Providers: Expansion of Dry Eye reimbursement could increase adoption of TearCare System.

Next Steps

• Announce complete fourth quarter and full year 2025 financial results in March 2026.
• Continue building a leading interventional eye care company.
• Work towards cash flow breakeven without requiring additional equity capital.

Key Dates

Recommendation

While the company demonstrated strong preliminary fourth-quarter revenue growth and effective cash management, the expected full-year revenue decline and a significant drop in Dry Eye segment revenue for the year present a mixed financial picture. Management's confidence in achieving cash flow breakeven without additional equity capital is a positive signal, but the overall performance suggests a 'hold' recommendation until complete audited results and clearer future guidance are available to assess the sustainability of Q4 momentum against full-year trends.

Keywords

Sight Sciences, SGHT, Financial Results, Fourth Quarter 2025, Full Year 2025, Revenue, Surgical Glaucoma, Dry Eye, Cash and Cash Equivalents, Eyecare Technology, Medical Devices, Ophthalmology, Glaucoma, Meibomian Gland Disease